The North East and North Cumbria (NENC) Medicines Committee are seeking NENC system-wide views on adoption of a draft guideline:
- Finerenone for treating chronic kidney disease in people with type 2 diabetes
Comments are welcomed from across the system, including residents and patients of the NENC.
Comments will be returned to the medicines committee, or its sub-committee, and used to inform implementation of the decisions in NENC.
All comments will be reviewed but please do not expect a personal reply as we do not routinely reply to all comments. It is important to include any relevant evidence to back up any suggestions and please keep comments concise where possible.
1. The messages sent from this form are transmitted via our host’s web server. If you have any security concerns about this process you can send your comments/feedback using your own email client to email@example.com
2. This consultation closes at 5pm on Tuesday 12th December 2023
|NENC DRAFT Guideline: Finerenone for treating chronic kidney disease in people with type 2 diabetes||033 DRAFT - Finerenone_CKD_type 2 diabetes_v4|